Business
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical
About this update from Nuvectis Pharma, Inc.
[{"type":"text","content":"Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 11-15, 2023 Boston, MA). Abstract Titles and PresentersPresentation Details2023 AACR Special Conference in Cancer Research: Ovarian CancerNXP800Activation of the integrated stress response by NXP800, an orally available, clinical-stage, investigational agent in ARID1A-mutated, platinum resistant ovarian cancerPresenter: Paul WorkmanThe Institute of Cancer Research London, United KingdomSession Title Proffered Talks ISession Type OralSession Date / Time October 6th, 9:50-10:50 AM2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNXP800From targeted phenotypic screen to NXP800: A clinical stage activator of the integrated stress response for the treatment of ARID1A-mutated ovarian carcinomaPresenter: Paul WorkmanThe Institute of Cancer Research London, United KingdomSession Title Drug ScreeningSession Type OralSession Date / Time October 14th, 4:00-5:40 PMNXP800Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors (B044)Presenter: Simon RodneyThe Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust London, United KingdomSession Title Poster Session BSession Type PosterSession Date / Time October 13th, 12:30-4:00 PMNXP900NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models (B162)Presenter: Neil O. CarragherUniversity of Edinburgh, Edinburgh, United KingdomSession Title Poster Session BSession Type PosterSession Date / Time October 13th, 12:30-4:00 PM About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of inn...